Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral sildenafil dose-ranging study in children with pulmonary arterial hypertension
2006-002235-25Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sildenafil in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Pfizer. Primary endpoint: Percent change in peak VO2 normalized to body weight from baseline to Week 16. Started Sep 2006; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2006-002235-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002235-25.